About
Francesco De Rubertis pioneered an asset-centric biotech model that builds companies around a few drug assets and scaled it by assembling Centessa Pharmaceuticals as a company-of-companies aggregating asset-centric subsidiaries.
Invests in
BiotechDigital HealthHealthtechMedical Devices
Deals · 2
Rivus Pharmaceuticals, Inc.Board seat
via Medicxi · filed Jan 2025 · $57M raise
Minerva NeurosciencesBoard seat
via Medicxi · filed Mar 2015 · $31M raise
Attribution from SEC filings, press coverage, and firm rosters.